Gold Derivatives Development as Prospective Anticancer Drugs for Breast Cancer Treatment
Authors:
- Ileana IeloIIIleana Ielo
- Domenico IacopettaDomenico Iacopetta
- Carmela SaturninoCarmela Saturnino
- Pasquale LongoPasquale Longo
- Maurilio GallettaMGMaurilio Galletta
- Dario DrommiDDDario Drommi
- Giuseppe RosaceGiuseppe Rosace
- Maria Stefania SinicropiMaria Stefania Sinicropi
- Maria Rosaria PlutinoMaria Rosaria Plutino
Open Access
- 26 February 2021
- journal article
- review article
- Published by MDPI AG in Applied Sciences
- Vol. 11 (5) , 2089
Abstract
Commonly used anticancer drugs are cisplatin and other platinum-based drugs. However, the use of these drugs in chemotherapy causes numerous side effects and the onset of frequent drug resistance phenomena. This review summarizes the most recent results on the gold derivatives used for their significant inhibitory effects on the in vitro proliferation of breast cancer cell models and for the consequences deriving from morphological changes in the same cells. In particular, the study discusses the antitumor activity of gold nanoparticles, gold (I) and (III) compounds, gold complexes and carbene-based gold complexes, compared with cisplatin. The results of screening studies of cytotoxicity and antitumor activity for the gold derivatives show that the death of cancer cells can occur intrinsically by apoptosis. Recent research has shown that gold (III) compounds with square planar geometries, such as that of cisplatin, can intercalate the DNA and provide novel anticancer agents. The gold derivatives described can make an important contribution to expanding the knowledge of medicinal bioorganometallic chemistry and broadening the range of anticancer agents available, offering improved characteristics, such as increased activity and/or selectivity, and paving the way for further discoveries and applications.Keywords
This publication has 78 references indexed in Scilit:
- Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancerJournal of Drug Assessment, 2020
- Are all cyclin-dependent kinases 4/6 inhibitors created equal?npj Breast Cancer, 2019
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerNew England Journal of Medicine, 2019
- CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future DirectionsCurrent Oncology Reports, 2019
- Global cancer control: responding to the growing burden, rising costs and inequalities in accessESMO Open, 2018
- Green synthesis: In-vitro anticancer activity of copper oxide nanoparticles against human cervical carcinoma cellsArabian Journal of Chemistry, 2017
- PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).Journal of Clinical Oncology, 2016
- 3-(Dipropylamino)-5-hydroxybenzofuro[2,3-f]quinazolin-1(2H)-one (DPA-HBFQ-1) plays an inhibitory role on breast cancer cell growth and progressionEuropean Journal of Medicinal Chemistry, 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast CancerCancer Discovery, 2011